Jim Lee
Company: Incyte
Job title: Group Vice President, Head of Inflammation and Autoimmunity
Seminars:
Speaker Q&A panel 10:40 am
day: Day Two
Targeting JAK Signalling in the Treatment of Vitiligo 9:50 am
Overview of vitiligo pathogenesis, psychosocial comorbidities and unmet medical need Discuss vitiligo competitive landscape, current challenges in conducting vitiligo clinical trials and regulatory path Demonstrate efficacy and safety of ruxolitinib (JAK inhibitor) cream and discuss subgroup analysis based on patient demographics and clinical characteristics from a phase 2 vitiligo clinical trialRead more
day: Day Two